209 results on '"Yu, Zhinuan"'
Search Results
2. Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study
3. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
4. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
5. Abstract CT150: Result of an open-label phase 2 trial of dual TORC1/TORC2 inhibitor onatasertib (ATG-008) in HBV+ advanced hepatocellular carcinoma (HCC) subjects who have received at least one prior line of systemic therapy (TORCH)
6. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
7. Additional file 1 of Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study
8. Phase 2 March Study: ATG-010 Plus Low Dose Dexamethasone in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Treated with an Immunomodulatory Agent (IMiD) and a Proteasome Inhibitor (PI)
9. ATG-010 Plus Low-Dose Dexamethasone (Sd) in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Received Chimeric Antigen Receptor T-Cell (CAR-T)
10. P-211: Phase 2 MARCH study: ATG-010 plus Dexamethasone in Chinese relapsed/refractory Multiple Myeloma (RRMM) patients previously treated with an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI)
11. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
12. The Effect of Migration Patterns on Exposure to HIV Prevention in a Migrant Community
13. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
14. Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
15. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function
16. Chronic and discrete stress as predictors of children's adjustment
17. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma
18. High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma
19. Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
20. Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
21. High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma
22. High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma
23. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
24. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
25. Lenalidomide (LEN) Maintenance Following High-Dose Melphalan and Autologous Stem Cell Transplant (ASCT) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): A Meta-Analysis of Overall Survival (OS)
26. The Multiple Myeloma Genome Project: Development of a Molecular Segmentation Strategy for Risk Stratification of Multiple Myeloma (MM)
27. Peripheral Neuropathy (PN) with Immunomodulatory Drugs in Patients with Multiple Myeloma (MM)
28. The Multiple Myeloma Genome Project: Development of a Molecular Segmentation Strategy for the Clinical Classification of Multiple Myeloma
29. Perpetrators, Victims, and Observers of Violence: Chronic and Non-Chronic Drug Users
30. Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS).
31. Predicting analysis time in events-driven clinical trials using accumulating time-to-event surrogate information
32. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide
33. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide
34. Analysis of Second-Line Lenalidomide Following Initial Relapse in the MM-015 Trial
35. Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma
36. The Efficacy and Safety of Lenalidomide Plus Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Patients With Impaired Renal Function
37. A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients≥ 65 years with newly diagnosed multiple myeloma (NDMM): continuous use of lenalidomide vs fixed-duration regimens
38. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma
39. Incidence of Varicella Zoster Virus (VZV) and Herpes Simplex Virus (HSV) Infections and Use of Prophylaxis in Lenalidomide-Treated Multiple Myeloma (MM) Patients (pts): An Analysis of MM Trials
40. A Phase III Study to Determine the Efficacy and Safety of Lenalidomide in Combination with Melphalan and Prednisone (MPR) in Elderly Patients with Newly Diagnosed Multiple Myeloma
41. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma
42. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
43. Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide/Dexamethasone Who Achieve a Complete or near Complete Response Have Longer Overall Survival and Time to Progression Compared with Patients Achieving a Partial Response
44. Lenalidomide/dexamethasone improves response and prolongs time to progression, even in patients with IgA multiple myeloma: A sub-analysis of the MM-009/010 studies
45. ECOG performance status affects efficacy, but not safety, of lenalidomide/dexamethasone in relapsed/refractory multiple myeloma (MM009/010 sub-analysis)
46. Dexamethasone dose adjustments seem to result in better efficacy and improved tolerability in patients with relapsed/refractory multiple myeloma who are treated with lenalidomide/dexamethasone (MM009/010 sub-analysis)
47. Prolonged overall survival with lenalidomide plus dexamethasone compared with dexamethasone alone in patients with relapsed or refractory multiple myeloma
48. Dexamethasone dose adjustments seem to result in better efficacy and improved tolerability in patients with relapsed/refractory multiple myeloma who are treated with lenalidomide/dexamethasone (MM009/010 sub-analysis)
49. Lenalidomide in combination with dexamethasone was more effective than dexamethasone in patients who have received prior thalidomide for relapsed or refractory multiple myeloma
50. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.